

Unrelated Donor HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples, recipient only samples and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

Variable	<u>Samples Available</u>	<u>Samples</u>	<u>Samples</u>
	<u>for Recipient and</u> <u>Donor</u> N (%)	<u>Available for</u> <u>Recipient Only</u> N (%)	<u>Available for</u> <u>Donor Only</u> N (%)
Number of patients	37744	10623	6882
Source of data			
CRF	21889 (58)	5634 (53)	4225 (61)
TED	15855 (42)	4989 (47)	2657 (39)
Number of centers	249	218	316
Disease at transplant			
AML	12782 (34)	3782 (36)	2223 (32)
ALL	5581 (15)	1464 (14)	1153 (17)
Other leukemia	1312 (3)	328 (3)	227 (3)
CML	3217 (9)	856 (8)	715 (10)
MDS	6063 (16)	1873 (18)	915 (13)
Other acute leukemia	388 (1)	119 (1)	72 (1)
NHL	3579 (9)	951 (9)	559 (8)
Hodgkins Lymphoma	800 (2)	162 (2)	120 (2)
Plasma Cell Disorders, MM	766 (2)	228 (2)	108 (2)
Other malignancies	54 (<1)	13 (<1)	17 (<1)
Breast cancer	7 (<1)	3 (<1)	1 (<1)
SAA	1191 (3)	297 (3)	280 (4)
Inherited abnormalities erythrocyte diff fxn	665 (2)	184 (2)	127 (2)
SCIDs	648 (2)	186 (2)	182 (3)
Inherited abnormalities of platelets	38 (<1)	9 (<1)	9 (<1)
Inherited disorders of metabolism	261 (1)	63 (1)	80 (1)
Histiocytic disorders	332 (1)	83 (1)	71 (1)
Autoimmune disorders	16 (<1)	7 (<1)	4 (<1)
Other	44 (<1)	15 (<1)	19 (<1)
AML Disease status at transplant			
CR1	6446 (50)	1924 (51)	970 (44)
CR2	2591 (20)	762 (20)	469 (21)
CR3+	257 (2)	70 (2)	50 (2)
Advanced or active disease	3341 (26)	989 (26)	687 (31)
Missing	143 (1)	37 (1)	43 (2)
ALL Disease status at transplant			
CR1	2643 (47)	730 (50)	464 (40)
CR2	1641 (29)	402 (27)	344 (30)
CR3+	466 (8)	120 (8)	111 (10)
Advanced or active disease	787 (14)	198 (14)	202 (18)
Missing	44 (1)	14 (1)	31 (3)
MDS Disease status at transplant			
Early	1233 (20)	327 (18)	212 (23)
Advanced	4332 (72)	1419 (76)	568 (63)

Refreshed January 2019

Variable	<u>Samples Available</u>	<u>Samples</u>	<u>Samples</u>
	<u>for Recipient and</u> <u>Donor</u> N (%)	<u>Available for</u> <u>Recipient Only</u> N (%)	<u>Available for</u> <u>Donor Only</u> N (%)
Missing	457 (8)	114 (6)	124 (14)
NHL Disease status at transplant			
CR1	446 (13)	158 (17)	58 (10)
CR2	664 (19)	166 (18)	93 (17)
CR3+	302 (9)	82 (9)	47 (8)
PR	431 (12)	108 (11)	78 (14)
Advanced	1655 (47)	419 (44)	271 (49)
Missing	50 (1)	9 (1)	9 (2)
Recipient age at transplant			
0-9 years	3381 (9)	833 (8)	898 (13)
10-19 years	3499 (9)	871 (8)	820 (12)
20-29 years	4018 (11)	1092 (10)	855 (12)
30-39 years	4481 (12)	1152 (11)	887 (13)
40-49 years	5945 (16)	1647 (16)	1104 (16)
50-59 years	7884 (21)	2177 (20)	1205 (18)
60-69 years	7285 (19)	2369 (22)	975 (14)
70+ years	1251 (3)	482 (5)	138 (2)
Median (Range)	46 (0-84)	49 (0-79)	40 (0-79)
Recipient race/ethnicity			
Caucasian, non-Hispanic	31488 (85)	8851 (85)	5200 (83)
African-American, non-Hispanic	1728 (5)	446 (4)	296 (5)
Asian, non-Hispanic	809 (2)	351 (3)	233 (4)
Pacific islander, non-Hispanic	49 (<1)	17 (<1)	12 (<1)
Native American, non-Hispanic	143 (<1)	47 (<1)	23 (<1)
Hispanic	2619 (7)	655 (6)	452 (7)
Other	44 (<1)	25 (<1)	21 (<1)
Unknown	864 (N/A)	231 (N/A)	645 (N/A)
Recipient sex			
Male	22065 (58)	6269 (59)	4075 (59)
Female	15679 (42)	4354 (41)	2807 (41)
Karnofsky score			
10-80	12440 (33)	3698 (35)	2071 (30)
90-100	23812 (63)	6374 (60)	4287 (62)
Missing	1492 (4)	551 (5)	524 (8)
HLA-A B DRB1 groups - low resolution			
<=3/6	21 (<1)	25 (<1)	1 (<1)
4/6	204 (1)	75 (1)	29 (<1)
5/6	5329 (14)	1325 (14)	977 (15)
6/6	31770 (85)	7921 (85)	5383 (84)
Unknown	420 (N/A)	1277 (N/A)	492 (N/A)
High-resolution HLA matches available out of 8			
<=5/8	834 (2)	66 (1)	27 (1)
6/8	1639 (4)	105 (2)	117 (3)
7/8	7450 (20)	1297 (19)	934 (23)
8/8	26608 (73)	5482 (79)	3001 (74)
Unknown	1213 (N/A)	3673 (N/A)	2803 (N/A)
HLA-DPB1 Match			

Refreshed January 2019

Variable	<u>Samples Available for Recipient and Donor</u> N (%)	<u>Samples Available for Recipient Only</u> N (%)	<u>Samples Available for Donor Only</u> N (%)
Double allele mismatch	8931 (30)	536 (25)	298 (28)
Single allele mismatch	16049 (54)	1101 (51)	549 (52)
Full allele matched	4646 (16)	522 (24)	206 (20)
Unknown	8118 (N/A)	8464 (N/A)	5829 (N/A)
High resolution release score			
No	397 (1)	156 (43)	362 (67)
Yes	28516 (99)	207 (57)	178 (33)
Unknown	8831 (N/A)	10260 (N/A)	6342 (N/A)
KIR typing available			
No	24082 (64)	10499 (99)	6842 (99)
Yes	13662 (36)	124 (1)	40 (1)
Graft type			
Marrow	14336 (38)	3792 (36)	3234 (47)
PBSC	23388 (62)	6730 (63)	3645 (53)
BM+PBSC	8 (<1)	6 (<1)	2 (<1)
BM+UCB	0	1 (<1)	0
PBSC+UCB	12 (<1)	94 (1)	1 (<1)
Number of cord units			
1	5 (100)	0	1 (100)
Conditioning regimen			
Myeloablative	24422 (65)	6581 (62)	4710 (68)
RIC/Nonmyeloablative	13151 (35)	4000 (38)	2093 (30)
TBD	171 (<1)	42 (<1)	79 (1)
Donor age at donation			
To Be Determined/NA	180 (<1)	1269 (12)	57 (1)
0-9 years	11 (<1)	15 (<1)	0
10-19 years	1043 (3)	307 (3)	145 (2)
20-29 years	16285 (43)	4188 (39)	2531 (37)
30-39 years	10995 (29)	2720 (26)	2168 (32)
40-49 years	7072 (19)	1608 (15)	1499 (22)
50+ years	2158 (6)	516 (5)	482 (7)
Median (Range)	31 (0-69)	30 (0-109)	33 (18-67)
Donor/Recipient CMV serostatus			
+/+	9249 (25)	2887 (28)	1677 (26)
+/-	4528 (12)	1376 (13)	860 (13)
-/+	12323 (33)	3133 (31)	2128 (33)
-/-	11116 (30)	2822 (28)	1874 (29)
CB - recipient +	0	4 (<1)	0
CB - recipient -	0	2 (<1)	0
CB - recipient CMV unknown	0	1 (<1)	0
Unknown	528 (N/A)	398 (N/A)	343 (N/A)
GvHD Prophylaxis			
Ex vivo T-cell depletion	1089 (3)	271 (3)	300 (4)
CD34 selection	665 (2)	282 (3)	105 (2)
Tacrolimus + MMF +- others	4514 (12)	1101 (10)	572 (8)
Tacrolimus + MTX +- others (except MMF)	16190 (43)	4697 (44)	1910 (28)
Tacrolimus + others (except MTX, MMF)	1971 (5)	682 (6)	273 (4)

Refreshed January 2019

Variable	<u>Samples Available</u>	<u>Samples</u>	<u>Samples</u>
	<u>for Recipient and</u> <u>Donor</u> N (%)	<u>Available for</u> <u>Recipient Only</u> N (%)	<u>Available for</u> <u>Donor Only</u> N (%)
Tacrolimus alone	919 (2)	285 (3)	117 (2)
CSA + MMF +- others (except Tacrolimus)	2583 (7)	581 (5)	566 (8)
CSA + MTX +- others (except Tacrolimus, MMF)	6473 (17)	1656 (16)	2128 (31)
CSA + others (except Tacrolimus, MTX, MMF)	985 (3)	297 (3)	283 (4)
CSA alone	462 (1)	115 (1)	267 (4)
Other GVHD prophylaxis	687 (2)	202 (2)	116 (2)
Missing	1206 (3)	454 (4)	245 (4)
Donor/Recipient sex match			
Male-Male	15602 (42)	4222 (40)	2727 (40)
Male-Female	9473 (25)	2543 (24)	1586 (23)
Female-Male	6359 (17)	1927 (18)	1323 (19)
Female-Female	6134 (16)	1702 (16)	1201 (18)
CB - recipient M	5 (<1)	53 (1)	0
CB - recipient F	7 (<1)	42 (<1)	1 (<1)
Unknown	164 (N/A)	134 (N/A)	44 (N/A)
Year of transplant			
1986-1990	349 (1)	45 (<1)	85 (1)
1991-1995	1795 (5)	448 (4)	610 (9)
1996-2000	3148 (8)	1113 (10)	894 (13)
2001-2005	5002 (13)	987 (9)	1433 (21)
2006-2010	9213 (24)	1853 (17)	1391 (20)
2011-2015	12850 (34)	3618 (34)	1714 (25)
2016-2019	5387 (14)	2559 (24)	755 (11)
Follow-up among survivors, Months			
N Eval	16177	4874	2672
Median (Range)	53 (0-344)	37 (0-325)	51 (0-337)

Unrelated Cord Blood Transplant Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired, recipient only and cord blood only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006-recipient only), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

Variable	<u>Samples Available</u>	<u>Samples</u>	<u>Samples</u>
	<u>for Recipient and</u> <u>Donor</u> N (%)	<u>Available for</u> <u>Recipient Only</u> N (%)	<u>Available for</u> <u>Donor Only</u> N (%)
Number of patients	5199	1233	1179
Source of data			
CRF	3988 (77)	952 (77)	795 (67)
TED	1211 (23)	281 (23)	384 (33)
Number of centers	144	127	188
Disease at transplant			
AML	1937 (37)	411 (33)	381 (32)
ALL	1060 (20)	259 (21)	268 (23)
Other leukemia	91 (2)	25 (2)	23 (2)
CML	112 (2)	29 (2)	28 (2)
MDS	502 (10)	123 (10)	100 (8)
Other acute leukemia	80 (2)	19 (2)	21 (2)
NHL	367 (7)	81 (7)	80 (7)
Hodgkins Lymphoma	93 (2)	25 (2)	21 (2)
Plasma Cell Disorders, MM	34 (1)	10 (1)	5 (<1)
Other malignancies	10 (<1)	0	0
SAA	89 (2)	28 (2)	21 (2)
Inherited abnormalities erythrocyte diff fxn	149 (3)	46 (4)	30 (3)
SCIDs	235 (5)	67 (5)	83 (7)
Inherited abnormalities of platelets	15 (<1)	3 (<1)	4 (<1)
Inherited disorders of metabolism	308 (6)	80 (6)	76 (6)
Histiocytic disorders	97 (2)	25 (2)	31 (3)
Autoimmune disorders	9 (<1)	0	1 (<1)
Other	11 (<1)	2 (<1)	6 (1)
AML Disease status at transplant			
CR1	966 (50)	219 (53)	192 (50)
CR2	548 (28)	104 (25)	104 (27)
CR3+	51 (3)	6 (1)	11 (3)
Advanced or active disease	364 (19)	80 (20)	72 (19)
Missing	8 (<1)	1 (<1)	2 (1)
ALL Disease status at transplant			
CR1	477 (45)	108 (42)	122 (46)
CR2	397 (37)	100 (39)	95 (35)
CR3+	118 (11)	35 (14)	28 (10)
Advanced or active disease	68 (6)	16 (6)	23 (9)
MDS Disease status at transplant			
Early	161 (32)	30 (25)	46 (46)
Advanced	306 (61)	86 (71)	43 (43)
Missing	34 (7)	5 (4)	10 (10)
NHL Disease status at transplant			

Variable	<u>Samples Available</u>	<u>Samples</u>	<u>Samples</u>
	<u>for Recipient and</u> <u>Donor</u>	<u>Available for</u> <u>Recipient Only</u>	<u>Available for</u> <u>Donor Only</u>
	N (%)	N (%)	N (%)
CR1	56 (15)	5 (6)	17 (22)
CR2	68 (19)	17 (21)	20 (25)
CR3+	42 (12)	10 (12)	9 (11)
PR	65 (18)	12 (15)	10 (13)
Advanced	133 (37)	36 (44)	22 (28)
Missing	0	1 (1)	1 (1)
Recipient age at transplant			
0-9 years	1562 (30)	456 (37)	440 (37)
10-19 years	681 (13)	143 (12)	160 (14)
20-29 years	490 (9)	86 (7)	91 (8)
30-39 years	507 (10)	104 (8)	113 (10)
40-49 years	546 (11)	123 (10)	108 (9)
50-59 years	731 (14)	149 (12)	141 (12)
60-69 years	599 (12)	151 (12)	117 (10)
70+ years	83 (2)	21 (2)	9 (1)
Median (Range)	27 (0-81)	22 (0-75)	19 (0-78)
Recipient race/ethnicity			
Caucasian, non-Hispanic	2908 (59)	739 (63)	650 (62)
African-American, non-Hispanic	743 (15)	167 (14)	136 (13)
Asian, non-Hispanic	300 (6)	70 (6)	74 (7)
Pacific islander, non-Hispanic	23 (<1)	2 (<1)	12 (1)
Native American, non-Hispanic	34 (1)	6 (1)	13 (1)
Hispanic	945 (19)	189 (16)	169 (16)
Other	0	1 (<1)	1 (<1)
Unknown	246 (N/A)	59 (N/A)	124 (N/A)
Recipient sex			
Male	2858 (55)	712 (58)	675 (57)
Female	2341 (45)	521 (42)	504 (43)
Karnofsky score			
10-80	1330 (26)	297 (24)	281 (24)
90-100	3728 (72)	851 (69)	829 (70)
Missing	141 (3)	85 (7)	69 (6)
HLA-A B DRB1 groups - low resolution			
<=3/6	70 (1)	27 (3)	5 (<1)
4/6	2051 (41)	393 (41)	411 (38)
5/6	2231 (45)	401 (42)	522 (48)
6/6	630 (13)	136 (14)	158 (14)
Unknown	217 (N/A)	276 (N/A)	83 (N/A)
High-resolution HLA matches available out of 8			
<=5/8	2478 (56)	405 (58)	474 (54)
6/8	1066 (24)	160 (23)	212 (24)
7/8	594 (13)	89 (13)	127 (14)
8/8	294 (7)	49 (7)	66 (8)
Unknown	767 (N/A)	530 (N/A)	300 (N/A)
HLA-DPB1 Match			
Double allele mismatch	682 (40)	42 (45)	39 (38)
Single allele mismatch	858 (50)	41 (44)	51 (50)

Refreshed January 2019

Variable	<u>Samples Available</u>	<u>Samples</u>	<u>Samples</u>
	<u>for Recipient and</u> Donor N (%)	<u>Available for</u> Recipient Only N (%)	<u>Available for</u> Donor Only N (%)
Full allele matched	160 (9)	10 (11)	12 (12)
Unknown	3499 (N/A)	1140 (N/A)	1077 (N/A)
High resolution release score			
No	156 (9)	32 (39)	31 (79)
Yes	1499 (91)	50 (61)	8 (21)
Unknown	3544 (N/A)	1151 (N/A)	1140 (N/A)
KIR typing available			
No	3935 (76)	1227 (>99)	1171 (99)
Yes	1264 (24)	6 (<1)	8 (1)
Cord blood number of units			
1	3609 (69)	0	913 (77)
2	1588 (31)	0	266 (23)
3	2 (<1)	0	0
Unknown	0 (N/A)	1233 (N/A)	0 (N/A)
Graft type			
UCB	4951 (95)	1138 (92)	1127 (96)
BM+UCB	1 (<1)	1 (<1)	0
PBSC+UCB	247 (5)	94 (8)	52 (4)
Conditioning regimen			
Myeloablative	3433 (66)	805 (65)	773 (66)
RIC/Nonmyeloablative	1756 (34)	426 (35)	403 (34)
TBD	10 (<1)	2 (<1)	3 (<1)
Donor age at donation			
To Be Determined/NA	137 (3)	76 (6)	65 (6)
0-9 years	4642 (89)	976 (79)	1029 (87)
10-19 years	273 (5)	104 (8)	52 (4)
20-29 years	44 (1)	21 (2)	7 (1)
30-39 years	43 (1)	27 (2)	12 (1)
40-49 years	24 (<1)	11 (1)	4 (<1)
50+ years	36 (1)	18 (1)	10 (1)
Median (Range)	4 (0-72)	4 (0-73)	3 (0-67)
Donor/Recipient CMV serostatus			
+/+	1204 (23)	251 (20)	245 (21)
+/-	532 (10)	119 (10)	113 (10)
-/+	966 (19)	223 (18)	217 (18)
-/-	655 (13)	153 (12)	165 (14)
CB - recipient +	1045 (20)	252 (20)	218 (18)
CB - recipient -	714 (14)	187 (15)	178 (15)
CB - recipient CMV unknown	83 (2)	48 (4)	43 (4)
GvHD Prophylaxis			
Ex vivo T-cell depletion	23 (<1)	9 (1)	4 (<1)
CD34 selection	182 (4)	70 (6)	39 (3)
Tacrolimus + MMF +- others	1379 (27)	309 (25)	182 (15)
Tacrolimus + MTX +- others (except MMF)	200 (4)	55 (4)	54 (5)
Tacrolimus + others (except MTX, MMF)	214 (4)	54 (4)	47 (4)
Tacrolimus alone	131 (3)	43 (3)	23 (2)
CSA + MMF +- others (except Tacrolimus)	2453 (47)	518 (42)	586 (50)

Refreshed January 2019

Variable	<u>Samples Available</u>	<u>Samples</u>	<u>Samples</u>
	<u>for Recipient and</u> <u>Donor</u>	<u>Available for</u> <u>Recipient Only</u>	<u>Available for</u> <u>Donor Only</u>
	N (%)	N (%)	N (%)
CSA + MTX +- others (except Tacrolimus, MMF)	92 (2)	27 (2)	39 (3)
CSA + others (except Tacrolimus, MTX, MMF)	311 (6)	104 (8)	134 (11)
CSA alone	57 (1)	15 (1)	44 (4)
Other GVHD prophylaxis	125 (2)	17 (1)	15 (1)
Missing	32 (1)	12 (1)	12 (1)
Donor/Recipient sex match			
CB - recipient M	2858 (55)	712 (58)	674 (57)
CB - recipient F	2341 (45)	521 (42)	504 (43)
CB - recipient sex unknown	0	0	1 (<1)
Year of transplant			
1996-2000	0	2 (<1)	4 (<1)
2001-2005	113 (2)	82 (7)	22 (2)
2006-2010	1783 (34)	406 (33)	425 (36)
2011-2015	2567 (49)	491 (40)	569 (48)
2016-2019	736 (14)	252 (20)	159 (13)
Follow-up among survivors, Months			
N Eval	2515	664	606
Median (Range)	52 (1-176)	37 (2-191)	49 (1-217)

Related Donor HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired, recipient only and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

Variable	<u>Samples Available</u>	<u>Samples</u>	<u>Samples</u>
	<u>for Recipient and</u> Donor N (%)	<u>Available for</u> Recipient Only N (%)	<u>Available for</u> Donor Only N (%)
Number of patients	6033	890	403
Source of data			
CRF	2317 (38)	276 (31)	161 (40)
TED	3716 (62)	614 (69)	242 (60)
Number of centers	82	63	51
Disease at transplant			
AML	1980 (33)	297 (33)	118 (29)
ALL	946 (16)	170 (19)	60 (15)
Other leukemia	141 (2)	26 (3)	19 (5)
CML	206 (3)	20 (2)	14 (3)
MDS	994 (16)	137 (15)	59 (15)
Other acute leukemia	81 (1)	14 (2)	3 (1)
NHL	631 (10)	84 (9)	58 (14)
Hodgkins Lymphoma	134 (2)	18 (2)	17 (4)
Plasma Cell Disorders, MM	182 (3)	30 (3)	15 (4)
Other malignancies	16 (<1)	0	0
Breast cancer	1 (<1)	0	0
SAA	261 (4)	31 (3)	12 (3)
Inherited abnormalities erythrocyte diff fxn	289 (5)	41 (5)	16 (4)
SCIDs	109 (2)	18 (2)	8 (2)
Inherited abnormalities of platelets	9 (<1)	0	0
Inherited disorders of metabolism	8 (<1)	0	0
Histiocytic disorders	31 (1)	2 (<1)	2 (<1)
Autoimmune disorders	5 (<1)	0	0
Other	9 (<1)	2 (<1)	2 (<1)
AML Disease status at transplant			
CR1	1215 (61)	189 (64)	72 (61)
CR2	312 (16)	33 (11)	12 (10)
CR3+	23 (1)	4 (1)	0
Advanced or active disease	423 (21)	69 (23)	32 (27)
Missing	7 (<1)	2 (1)	2 (2)
ALL Disease status at transplant			
CR1	597 (63)	112 (66)	43 (72)
CR2	257 (27)	35 (21)	10 (17)
CR3+	39 (4)	5 (3)	2 (3)
Advanced or active disease	53 (6)	18 (11)	5 (8)
MDS Disease status at transplant			
Early	175 (18)	19 (14)	6 (10)
Advanced	789 (79)	114 (83)	51 (86)
Missing	30 (3)	4 (3)	2 (3)

Refreshed January 2019

Variable	<u>Samples Available for Recipient and Donor</u> N (%)	<u>Samples Available for Recipient Only</u> N (%)	<u>Samples Available for Donor Only</u> N (%)
NHL Disease status at transplant			
CR1	103 (16)	19 (23)	8 (14)
CR2	124 (20)	14 (17)	11 (19)
CR3+	70 (11)	6 (7)	2 (3)
PR	58 (9)	11 (13)	6 (10)
Advanced	270 (43)	32 (39)	31 (53)
Missing	2 (<1)	1 (1)	0
Recipient age at transplant			
0-9 years	556 (9)	70 (8)	29 (7)
10-19 years	629 (10)	65 (7)	25 (6)
20-29 years	484 (8)	93 (10)	37 (9)
30-39 years	470 (8)	79 (9)	33 (8)
40-49 years	844 (14)	121 (14)	57 (14)
50-59 years	1450 (24)	208 (23)	102 (25)
60-69 years	1402 (23)	225 (25)	109 (27)
70+ years	198 (3)	29 (3)	11 (3)
Median (Range)	50 (0-78)	51 (0-76)	52 (0-74)
Recipient race/ethnicity			
Caucasian, non-Hispanic	3899 (67)	485 (58)	264 (68)
African-American, non-Hispanic	690 (12)	89 (11)	43 (11)
Asian, non-Hispanic	269 (5)	73 (9)	22 (6)
Pacific islander, non-Hispanic	22 (<1)	3 (<1)	0
Native American, non-Hispanic	23 (<1)	1 (<1)	0
Hispanic	909 (16)	184 (22)	60 (15)
Unknown	221 (N/A)	55 (N/A)	14 (N/A)
Recipient sex			
Male	3540 (59)	533 (60)	235 (58)
Female	2493 (41)	357 (40)	168 (42)
Karnofsky score			
10-80	2091 (35)	367 (41)	164 (41)
90-100	3801 (63)	502 (56)	221 (55)
Missing	141 (2)	21 (2)	18 (4)
Graft type			
Marrow	1660 (28)	209 (23)	115 (29)
PBSC	4348 (72)	673 (76)	284 (70)
BM+PBSC	6 (<1)	3 (<1)	0
BM+UCB	19 (<1)	5 (1)	1 (<1)
PBSC+UCB	0	0	3 (1)
Conditioning regimen			
Myeloablative	3530 (59)	518 (58)	217 (54)
RIC/Nonmyeloablative	2469 (41)	367 (41)	179 (44)
TBD	34 (1)	5 (1)	7 (2)
Donor age at donation			
To Be Determined/NA	34 (1)	4 (<1)	2 (<1)
0-9 years	406 (7)	43 (5)	19 (5)
10-19 years	571 (9)	75 (8)	28 (7)
20-29 years	731 (12)	116 (13)	46 (11)

Refreshed January 2019

Variable	<u>Samples Available</u>	<u>Samples</u>	<u>Samples</u>
	<u>for Recipient and</u> <u>Donor</u> N (%)	<u>Available for</u> <u>Recipient Only</u> N (%)	<u>Available for</u> <u>Donor Only</u> N (%)
30-39 years	738 (12)	130 (15)	66 (16)
40-49 years	1004 (17)	148 (17)	57 (14)
50+ years	2549 (42)	374 (42)	185 (46)
Median (Range)	46 (0-81)	45 (0-79)	47 (0-76)
Donor/Recipient CMV serostatus			
+/+	2457 (41)	431 (49)	177 (45)
+/-	650 (11)	62 (7)	49 (13)
-/+	1490 (25)	202 (23)	87 (22)
-/-	1347 (23)	178 (20)	77 (20)
Unknown	89 (N/A)	17 (N/A)	13 (N/A)
GvHD Prophylaxis			
Ex-vivo T-cell depletion	65 (1)	19 (2)	3 (1)
CD34 selection	80 (1)	26 (3)	7 (2)
Post-CY + other(s)	1057 (18)	148 (17)	70 (17)
Post-CY alone	32 (1)	8 (1)	3 (1)
TAC + MMF +- other(s) (except post-CY)	698 (12)	59 (7)	25 (6)
TAC + MTX +- other(s) (except MMF, post-CY)	2520 (42)	331 (37)	196 (49)
TAC + other(s) (except MMF, MTX, post-CY)	557 (9)	195 (22)	45 (11)
TAC alone	51 (1)	7 (1)	2 (<1)
CSA + MMF +- other(s) (except post-CY)	157 (3)	11 (1)	4 (1)
CSA + MTX +- other(s) (except MMF, post-CY)	497 (8)	52 (6)	26 (6)
CSA + other(s) (except MMF, MTX, post-CY)	57 (1)	9 (1)	2 (<1)
CSA alone	53 (1)	8 (1)	2 (<1)
Other(s)	90 (1)	7 (1)	6 (1)
Missing	119 (2)	10 (1)	12 (3)
Donor/Recipient sex match			
Male-Male	1954 (32)	329 (37)	140 (35)
Male-Female	1305 (22)	168 (19)	83 (21)
Female-Male	1569 (26)	199 (22)	94 (23)
Female-Female	1184 (20)	188 (21)	82 (20)
CB - recipient M	15 (<1)	4 (<1)	1 (<1)
CB - recipient F	4 (<1)	1 (<1)	3 (1)
Unknown	2 (N/A)	1 (N/A)	0 (N/A)
Year of transplant			
2006-2010	511 (8)	48 (5)	38 (9)
2011-2015	3239 (54)	455 (51)	206 (51)
2016-2019	2283 (38)	387 (43)	159 (39)
Follow-up among survivors, Months			
N Eval	3825	575	258
Median (Range)	25 (1-126)	23 (2-121)	25 (2-109)